Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vbi Vaccines Inc CS (VBIV)

Vbi Vaccines Inc CS (VBIV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 847,387
  • Shares Outstanding, K 256,008
  • Annual Sales, $ 1,060 K
  • Annual Income, $ -46,230 K
  • 60-Month Beta 2.04
  • Price/Sales 774.54
  • Price/Cash Flow N/A
  • Price/Book 5.22
Trade VBIV with:

Options Overview

Details
  • Implied Volatility 85.09%
  • Historical Volatility 53.06%
  • IV Percentile 21%
  • IV Rank 28.03%
  • IV High 171.51% on 09/21/20
  • IV Low 51.42% on 08/10/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 1,623
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 4,171
  • Open Int (30-Day) 39,738

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.92 +11.00%
on 08/23/21
3.81 -14.96%
on 09/01/21
+0.31 (+10.58%)
since 08/20/21
3-Month
2.73 +18.68%
on 08/17/21
4.31 -24.83%
on 06/29/21
-0.68 (-17.35%)
since 06/18/21
52-Week
2.07 +56.52%
on 11/10/20
4.83 -32.92%
on 02/10/21
-0.34 (-9.50%)
since 09/18/20

Most Recent Stories

More News
The Surge in New Cases Reinforces the Importance of a Healthy Lifestyle

/PRNewswire/ -- While most of the economy has reopened, the number of new cases is once again on the rise. This time, two variants of COVID-19, the delta and lambda variants, are causing the numbers of...

TOMDF : 0.0428 (+1.90%)
AGEN : 5.70 (-2.23%)
HOLX : 77.73 (+0.13%)
VBIV : 3.18 (-3.93%)
IBIO : 1.1500 (-6.50%)
VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 12.50% and -73.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

VBIV : 3.18 (-3.93%)
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported financial results for the second...

VBIV : 3.18 (-3.93%)
AGEN : 5.70 (-2.23%)
Earnings Preview: VBI Vaccines, Inc. (VBIV) Q2 Earnings Expected to Decline

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBIV : 3.18 (-3.93%)
VBI Vaccines Appoints Linda Bain to Board of Directors

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Linda Bain, Chief Financial...

VBIV : 3.18 (-3.93%)
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported that the American Medical Association...

VBIV : 3.18 (-3.93%)
Thinking about buying stock in Exela Technologies, Cerevel Therapeutics, Verb Technology, Avinger, or VBI Vaccines?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, CERE, VERB, AVGR, and VBIV.

XELA : 1.94 (-5.37%)
AVGR : 0.8200 (-4.65%)
CERE : 37.33 (-0.64%)
VBIV : 3.18 (-3.93%)
VERB : 1.8000 (-5.76%)
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19

VBI Vaccines Inc. (Nasdaq:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced positive Phase 1 data from its Phase...

VBIV : 3.18 (-3.93%)
Thinking about buying stock in SeaChange, Chindata Group, VBI Vaccines, Drive Shack, or Surgalign?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, CD, VBIV, DS, and SRGA.

CD : 9.69 (-8.06%)
SEAC : 1.0300 (-3.74%)
SRGA : 1.3900 (+0.72%)
VBIV : 3.18 (-3.93%)
DS : 2.70 (-5.26%)
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

--Results support further clinical evaluation of BRII-179 (VBI-2601) as an immunomodulator in combination with other treatment modalities as a potential functional cure for chronic HBV infection

VBIV : 3.18 (-3.93%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus...

See More

Key Turning Points

3rd Resistance Point 3.56
2nd Resistance Point 3.44
1st Resistance Point 3.38
Last Price 3.18
1st Support Level 3.20
2nd Support Level 3.08
3rd Support Level 3.02

See More

52-Week High 4.83
Fibonacci 61.8% 3.78
Fibonacci 50% 3.45
Last Price 3.18
Fibonacci 38.2% 3.12
52-Week Low 2.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar